Cerebrospinal fluid (CSF) studies consistently show that CSF levels of amyloid-beta 1-42 (Aβ) are reduced and tau levels increased prior to the onset of cognitive decline related to Alzheimer's disease (AD). However, the preclinical prediction accuracy for low CSF Aβ levels, a surrogate for brain Aβ deposits, is not high. Moreover, the pathology data suggests a course initiated by tauopathy contradicting the contemporary clinical view of an Aβ initiated cascade. CSF Aβ and tau data from 3 normal aging cohorts (45-90 years) were combined to test both cross-sectional (n = 766) and longitudinal (n = 651) hypotheses: 1) that the relationship between CSF levels of Aβ and tau are not linear over the adult life-span; and 2) that non-linear models ...
Decreased delayed recall, decreased amyloid-beta peptides (A beta(1-42)), and increased tau protein ...
Despite well-described temporal staging, the relationships between Alzheimer’s disease (AD) biomarke...
AbstractBackgroundThe need to recognize Alzheimer’s disease (AD) as early as possible led us to eval...
Cerebrospinal fluid (CSF) studies consistently show that CSF levels of amyloid-beta 1-42 (Aβ) are re...
Cerebrospinal fluid (CSF) studies consistently show that CSF levels of amyloid-beta 1-42 (Aβ42) are ...
International audienceOBJECTIVE: To investigate the relationship between cerebrospinal fluid (CSF) β...
ObjectiveTo investigate the relationship between cerebrospinal fluid (CSF) β-amyloid peptide (Aβ42) ...
Objective To elucidate the relationship between the two hallmark proteins of Alzheimer's disease (...
INTRODUCTION: Levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) and Tau proteins change in Alzheime...
BACKGROUND: Low amyloid \u3b242 (A\u3b242) and high total tau and phosphorylated tau (p-tau) conce...
Background: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD)...
BACKGROUND: Abnormal cerebrospinal fluid (CSF) biomarker levels predict development of Alzheimer dis...
AbstractIntroductionBiomarkers are urgently needed for the critical yet understudied preclinical sta...
Objective: To study risk factors for decreasing aβ1–42 concentrations in cerebrospinal fluid (CSF) i...
Background: Amyloid beta 1–43 (Aβ43) may be a useful additional biomarker for diagnosing Alzheimer’s...
Decreased delayed recall, decreased amyloid-beta peptides (A beta(1-42)), and increased tau protein ...
Despite well-described temporal staging, the relationships between Alzheimer’s disease (AD) biomarke...
AbstractBackgroundThe need to recognize Alzheimer’s disease (AD) as early as possible led us to eval...
Cerebrospinal fluid (CSF) studies consistently show that CSF levels of amyloid-beta 1-42 (Aβ) are re...
Cerebrospinal fluid (CSF) studies consistently show that CSF levels of amyloid-beta 1-42 (Aβ42) are ...
International audienceOBJECTIVE: To investigate the relationship between cerebrospinal fluid (CSF) β...
ObjectiveTo investigate the relationship between cerebrospinal fluid (CSF) β-amyloid peptide (Aβ42) ...
Objective To elucidate the relationship between the two hallmark proteins of Alzheimer's disease (...
INTRODUCTION: Levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) and Tau proteins change in Alzheime...
BACKGROUND: Low amyloid \u3b242 (A\u3b242) and high total tau and phosphorylated tau (p-tau) conce...
Background: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD)...
BACKGROUND: Abnormal cerebrospinal fluid (CSF) biomarker levels predict development of Alzheimer dis...
AbstractIntroductionBiomarkers are urgently needed for the critical yet understudied preclinical sta...
Objective: To study risk factors for decreasing aβ1–42 concentrations in cerebrospinal fluid (CSF) i...
Background: Amyloid beta 1–43 (Aβ43) may be a useful additional biomarker for diagnosing Alzheimer’s...
Decreased delayed recall, decreased amyloid-beta peptides (A beta(1-42)), and increased tau protein ...
Despite well-described temporal staging, the relationships between Alzheimer’s disease (AD) biomarke...
AbstractBackgroundThe need to recognize Alzheimer’s disease (AD) as early as possible led us to eval...